Author ORCID Identifier

Date Available


Year of Publication


Degree Name

Master of Science (MS)

Document Type

Master's Thesis




Pharmaceutical Sciences

First Advisor

Penni Black


Recent lung cancer research has led to advancements in molecular immunology, resulting in development of small molecule inhibitors, or immune checkpoint inhibitors, that propagate an anti-tumor T cell response. Despite increased overall and progression-free survival with reduced adverse effects compared to traditional chemotherapy, treating advanced stage lung adenocarcinoma patients remains non-curative, and evidence of non-responders or tumor recurrence to immune checkpoint inhibitor therapy is growing. Also, compared to traditional chemotherapy, there is a lower percentage of patients who respond to small molecule inhibitors. In this analysis of proteomic and genomic data from The Cancer Proteome Atlas and Global Data Commons cancer databases, as well as clinical outcomes data from Phase II POPLAR and Phase III OAK clinical trials, we discuss possible prognostic and predictive factors of immunotherapy in the treatment of advanced non-small-cell lung carcinoma.

Digital Object Identifier (DOI)